Share this page:
SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dose of the mRNA-1273 vaccine (Moderna) and 95% efficacy at 7 days after the second dose of the BNT162b2 vaccine (Pfizer).
Date Last Updated (Year-Month-Day)
Keehner, Jocelyn, Lucy E. Horton, Michael A. Pfeffer, Christopher A. Longhurst, Robert T. Schooley, Judith S. Currier, Shira R. Abeles, and Francesca J. Torriani. 2021. "SARS-CoV-2 Infection after Vaccination in Health Care Workers in California." New England Journal of Medicine.
Free online on NEJM.